BI 690517 clinical trials

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

This study looks at a new medicine, BI 690517, combined with empagliflozin, for adults with chronic kidney disease. It aims to see if this combination can help slow down kidney disease progression and protect the heart, for people with and without type 2 diabetes.